Surgery – Magnetic field applied to body for therapy
Reexamination Certificate
2006-02-14
2006-02-14
Lacyk, John P. (Department: 3736)
Surgery
Magnetic field applied to body for therapy
C977S726000
Reexamination Certificate
active
06997863
ABSTRACT:
Disclosed are therapeutic methods for the treatment of disease material involving administration of a thermotherapeutic magnetic composition, which contains single-domain magnetic particles attached to a target-specific ligand, to a patient and application of an alternating magnetic field to inductively heat the thermotherapeutic magnetic composition. Also disclosed are methods of administering the thermotherapeutic magnetic material composition. The thermotherapeutic methods may be used where the predetermined target is associated with diseases, such as cancer, diseases of the immune system, and pathogen-borne diseases, and undesirable targets, such as toxins, reactions associated with organ transplants, hormone-related diseases, and non-cancerous diseased cells or tissue.
REFERENCES:
patent: 4106488 (1978-08-01), Gordon
patent: 4303636 (1981-12-01), Gordon
patent: 4312364 (1982-01-01), Convert
patent: 4323056 (1982-04-01), Borrelli
patent: 4392040 (1983-07-01), Rand
patent: 4452773 (1984-06-01), Molday
patent: 4454234 (1984-06-01), Czerlinski
patent: 4545368 (1985-10-01), Rand
patent: RE32066 (1986-01-01), Leveen
patent: 4569836 (1986-02-01), Gordon
patent: 4574782 (1986-03-01), Borrelli
patent: 4590922 (1986-05-01), Gordon
patent: 4610241 (1986-09-01), Gordon
patent: 4622952 (1986-11-01), Gordon
patent: 4662359 (1987-05-01), Gordon
patent: 4678667 (1987-07-01), Meares
patent: 4708718 (1987-11-01), Daniels
patent: 4735796 (1988-04-01), Gordon
patent: 4753894 (1988-06-01), Frankel
patent: 4758429 (1988-07-01), Gordon
patent: 4767611 (1988-08-01), Gordon
patent: 4813399 (1989-03-01), Gordon
patent: 4889120 (1989-12-01), Gordon
patent: 4923437 (1990-05-01), Gordon
patent: 4950221 (1990-08-01), Gordon
patent: 4983159 (1991-01-01), Rand
patent: 4996991 (1991-03-01), Gordon
patent: 5043101 (1991-08-01), Gordon
patent: 5067952 (1991-11-01), Gudov et al.
patent: 5087438 (1992-02-01), Gordon
patent: 5099756 (1992-03-01), Franconi
patent: 5128147 (1992-07-01), Leveen
patent: 5169774 (1992-12-01), Frankel
patent: 5203782 (1993-04-01), Gudov
patent: 5300750 (1994-04-01), Carter, Jr. et al.
patent: 5411730 (1995-05-01), Kirpotin
patent: 5441746 (1995-08-01), Chagnon
patent: 5468210 (1995-11-01), Matsui
patent: 5506343 (1996-04-01), Kufe
patent: 5547682 (1996-08-01), Chagnon
patent: 5612019 (1997-03-01), Gordon
patent: 5620480 (1997-04-01), Rudie
patent: 5622686 (1997-04-01), Gordon
patent: 5629197 (1997-05-01), Ring
patent: 5658234 (1997-08-01), Dunlavy
patent: 5677171 (1997-10-01), Hudziak
patent: 5705157 (1998-01-01), Greene
patent: 5720954 (1998-02-01), Hudziak
patent: 5772997 (1998-06-01), Hudziak
patent: 5859206 (1999-01-01), Vandlen
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio
patent: 5916539 (1999-06-01), Pilgrimm
patent: 5922845 (1999-07-01), Deo
patent: 5935866 (1999-08-01), Chagnon
patent: 5958374 (1999-09-01), Meares
patent: 5968511 (1999-10-01), Akita
patent: 6008203 (1999-12-01), Magnani
patent: 6015567 (2000-01-01), Hudziak
patent: 6037129 (2000-03-01), Cole
patent: 6054561 (2000-04-01), Ring
patent: 6074337 (2000-06-01), Tucker
patent: 6149576 (2000-11-01), Gray
patent: 6165440 (2000-12-01), Esenaliev
patent: 6165464 (2000-12-01), Hudziak
patent: 6167313 (2000-12-01), Gray
patent: 6190870 (2001-02-01), Schmitz
patent: 6242196 (2001-06-01), Spiegelman
patent: 6252050 (2001-06-01), Ashkenazi
patent: 6281202 (2001-08-01), Magnani
patent: 6303755 (2001-10-01), Deo
patent: 6344203 (2002-02-01), Sandrin
patent: 6347633 (2002-02-01), Groth
patent: 6387371 (2002-05-01), Hudziak
patent: 6387888 (2002-05-01), Mincheff
patent: 6391026 (2002-05-01), Hung
patent: 6541039 (2003-04-01), Lesniak et al.
patent: 6638494 (2003-10-01), Pilgrimm
patent: 2002/0052594 (2002-05-01), Goldenberg
patent: 0040512 (1981-11-01), None
patent: 0136530 (1985-04-01), None
patent: 0333381 (1989-09-01), None
patent: 0400940 (1990-12-01), None
patent: 0543498 (1993-05-01), None
patent: 00344270 (1994-11-01), None
patent: 0913167 (1999-05-01), None
patent: 0673255 (2001-08-01), None
patent: 1244767 (1989-09-01), None
patent: WO9411023 (1994-05-01), None
patent: WO 97/43005 (1997-11-01), None
patent: WO 99/19000 (1999-04-01), None
patent: WO 00/52714 (2000-09-01), None
patent: WO 01/500 (2001-02-01), None
patent: WO 01/501 (2001-02-01), None
patent: WO 01/17611 (2001-03-01), None
patent: WO 01/37721 (2001-05-01), None
Peasley, K.W. “Destruction of human immunodeficiency-infected cells by ferrofluid particles manipulated by an external magnetic field: mechanical disruption and selective introduction of cytotoxic or antiretroviral substances into target cells.” Medical Hypotheses, 1996, pp. 5-12, vol. 46, No. 1, England (ABSTRACT).
Torchilin, V.P., et al. “Magnetic sephadex as a carrier for enzyme immobilization and drug targeting.” Journal of Biomedical Materials Research, 1985, pp. 461-466, vol. 19, No. 4, United States (ABSTRACT).
Molina, M.A., et al. “Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.” Cancer Research 2001, pp. 4744-4749, Jun. 15;61(12) (ABSTRACT).
Wong, C., et al. “Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells.” Cancer Immunol. Immunother. 2001, pp. 93-101, Apr.;50(2). (ABSTRACT).
Winthrop, M.D., et al. “Development of a hyperimmune anti-MUC-1 single chain antibody fragment phage display library for targeting breast cancer.” Clinical Cancer Research 1999, pp. 3088-3094, Oct.;5(10 suppl.).
Richman, C.M., et al. “Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.” Crit Rev Oncol Hematol 2001,pp. 25-35, vol. 38, Ireland (ABSTRACT).
Kobayashi, T., et al. “Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes”. Japanese Journal of Cancer Research 2001 vol. 92 No. 10 (ABSTRACT).
Young, A.J., et al. “A pulsed power supply system for producing high intensity magnetic and electric fields for medical applications”. IEEE Conference Record—Abstracts. PPPS-2001 Pulsed Power Plasma Science 2001. 28th IEEE International Conference on Plasma Science and 13th IEEE International Pulsed Power Conference (Cat. No. 01CH37255) 2001, pp. 322 USA (ABSTRACT).
Peterson, J.A., et al. “Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas”, Cancer Res. 1997, pp. 1103-1108, vol. 57(6), (ABSTRACT).
Diaz, A.K., et al. “Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast”, Breast J. 2001, pp. 40-45, vol. 7(1), (ABSTRACT).
Barratt-Boyles, S.M. “Making the most of mucin: a novel target for tumor immunotherapy”, Cancer Immunol. Immunother. 1996, pp. 142-151, vol. 43(3), (ABSTRACT).
Menard, S.M., et al. “Role of Her2 gene overexpression in breast carcinoma”, J. Cell Physiol. 2000, pp. 150-162, vol. 182(2), (ABSTRACT).
Hadden, J.W., “The immunology and immunotherapy of breast cancer: an update”, Int. J. Immunopharacol. 1999, pp. 79-101, vol. 21(2), (ABSTRACT).
Tucker, R.D., et al. “Defining the heating characteristics of ferromagnetic implants using calorimetry” J. of Biomedical Materials Research, 2000, vol. 53, pp. 791-798.(ABSTRACT).
Takegami, K., et al. “New ferromagnetic bone cement for local hyperthermia” J. Biomedical Materials Research, 1998, vol. 43, pp. 210-214. .(ABSTRACT).
Paulus, J.A., et al. “Corrosion analysis of NiCu and PdCo thermal seed alloys used as interstitial hyperthermia implants”, 1997, vol. 18, pp. 1609-1614. .(ABSTRACT).
Graef, G.L. “Materials for low Curie temperature induction heating of tumors (Hyperthermia)” Ph.D. Dissertation, University of Arizona, 1991 .(ABSTRACT).
Petrarca, C. et al. “Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by i
Ardman Blair
Braunhut Susan J.
Ellis-Busby Diane
Foreman Allan
Gwost Douglas U.
Elandjian Lucy
Lacyk John P.
Miller Raymond A.
Pepper Hamilton LLP
Triton BioSystems, Inc.
LandOfFree
Thermotherapy via targeted delivery of nanoscale magnetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thermotherapy via targeted delivery of nanoscale magnetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thermotherapy via targeted delivery of nanoscale magnetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668537